The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis.

ABSTRACT:

Introduction

Antiresorptive therapies are commonly utilized to mitigate and prevent skeletal-related-events in patients with metastatic osseous disease. However, limited data exists on the incidence or factors associated with prescription of antiresorptives or their effects on the incidence of pathologic fractures in patients with osseous metastatic disease. The aims of this study were to determine 1) the proportion of patients with osseous metastasis who receive antiresorptive therapy and sustain a pathologic fracture within 2-years of a new diagnosis, 2) factors associated with sustaining a pathologic fracture, and 3) factors are associated with the likelihood of receiving antiresorptive therapy.

Methods

Between January 2010 and October 2021, 1,492,301 patients with a new

SUBMITTER: Agarwal AR 

PROVIDER: S-EPMC10585374 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature